OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]Status:Awaiting developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over TS ID 10642Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Upadacitinib for treating giant cell arteritis [ID6299]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years ID 6492Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia TS ID 11977Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over ID6457Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over ID6486Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC